Archives of Medical Science (Nov 2021)
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
- Maciej Banach,
- Paweł Burchardt,
- Krzysztof Chlebus,
- Piotr Dobrowolski,
- Dariusz Dudek,
- Krzysztof Dyrbuś,
- Mariusz Gąsior,
- Piotr Jankowski,
- Jacek Jóźwiak,
- Longina Kłosiewicz-Latoszek,
- Irina Kowalska,
- Maciej Małecki,
- Aleksander Prejbisz,
- Michał Rakowski,
- Jacek Rysz,
- Bogdan Solnica,
- Dariusz Sitkiewicz,
- Grażyna Sygitowicz,
- Grażyna Sypniewska,
- Tomasz Tomasik,
- Adam Windak,
- Dorota Zozulińska-Ziółkiewicz,
- Barbara Cybulska
Affiliations
- Maciej Banach
- ORCiD
- Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Lodz, Poland
- Paweł Burchardt
- ORCiD
- Department of Hypertensiology, Angiology, and Internal Medicine, K. Marcinkowski Poznan University of Medical Science, Poznan, Poland
- Krzysztof Chlebus
- ORCiD
- First Department and Chair of Cardiology, Medical University of Gdansk, Gdansk, Poland
- Piotr Dobrowolski
- ORCiD
- Department of Hypertension, National Institute of Cardiology, Warsaw, Poland
- Dariusz Dudek
- ORCiD
- Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland
- Krzysztof Dyrbuś
- ORCiD
- 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland; Silesian Center for Heart Diseases in Zabrze, Poland
- Mariusz Gąsior
- ORCiD
- 3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland; Silesian Center for Heart Diseases in Zabrze, Poland
- Piotr Jankowski
- ORCiD
- Department of Internal Medicine and Geriatric Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland
- Jacek Jóźwiak
- ORCiD
- Department of Family Medicine and Public Health, Institute of Medical Sciences, Faculty of Medicine, University of Opole, Opole, Poland
- Longina Kłosiewicz-Latoszek
- ORCiD
- National Institute of Public Health NIH – National Research Institute, Warsaw, Poland
- Irina Kowalska
- ORCiD
- Department of Internal Medicine and Metabolic Diseases, Medical University of Bialystok, Bialystok, Poland
- Maciej Małecki
- ORCiD
- Department and Chair of Metabolic Diseases, Jagiellonian University Medical College, Krakow, Poland
- Aleksander Prejbisz
- ORCiD
- Department of Hypertension, National Institute of Cardiology, Warsaw, Poland
- Michał Rakowski
- ORCiD
- Department of Molecular Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
- Jacek Rysz
- ORCiD
- Chair of Nephrology, Arterial Hypertension, and Family Medicine, Medical University of Lodz, Lodz, Poland
- Bogdan Solnica
- ORCiD
- Chair of Clinical Biochemistry, Jagiellonian University Medical College, Krakow, Poland
- Dariusz Sitkiewicz
- ORCiD
- Department of Clinical Chemistry and Laboratory Diagnostics, Medical University of Warsaw, Warsaw, Poland
- Grażyna Sygitowicz
- ORCiD
- Department of Clinical Chemistry and Laboratory Diagnostics, Medical University of Warsaw, Warsaw, Poland
- Grażyna Sypniewska
- ORCiD
- Department of Laboratory Medicine, L. Rydygier Medical College in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
- Tomasz Tomasik
- ORCiD
- Chair of Family Medicine, Jagiellonian University Medical College, Krakow, Poland
- Adam Windak
- ORCiD
- Chair of Family Medicine, Jagiellonian University Medical College, Krakow, Poland
- Dorota Zozulińska-Ziółkiewicz
- ORCiD
- Department and Chair of Internal Medicine and Diabetology, K. Marcinkowski Poznan University of Medical Sciences, Poznan, Poland
- Barbara Cybulska
- ORCiD
- National Institute of Public Health NIH – National Research Institute, Warsaw, Poland
- DOI
- https://doi.org/10.5114/aoms/141941
- Journal volume & issue
-
Vol. 17,
no. 6
pp. 1447 – 1547
Abstract
In Poland there are still nearly 20 million individuals with hypercholesterolaemia, most of them are unaware of their condition; that is also why only ca. 5% of patients with familial hypercholesterolaemia have been diagnosed; that is why other rare cholesterol metabolism disorders are so rarely diagnosed in Poland. Let us hope that these guidelines, being an effect of work of experts representing 6 main scientific societies, as well as the network of PoLA lipid centers being a part of the EAS lipid centers, certification of lipidologists by PoLA, or the growing number of centers for rare diseases, with a network planned by the Ministry of Health, improvements in coordinated care for patients after myocardial infarction (KOS-Zawał), reimbursement of innovative agents, as well as introduction in Poland of an effective primary prevention program, will make improvement in relation to these unmet needs in diagnostics and treatment of lipid disorders possible.
Keywords
